--- title: "Enanta Pharmaceuticals (ENTA) news: offering and lawsuit" url: "https://aibio.space/companies/enanta-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ENTA offering and lawsuit news: Enanta Pharmaceuticals files for up to $75,000,000 at-the-market stock sales. Enanta Pharmaceuticals, Inc." --- ENTA Enanta Pharmaceuticals, Inc. NASDAQ · United States # Enanta Pharmaceuticals (ENTA) news ENTA offering and lawsuit news Legal · 2026-10-29 ## [European patent court rules Enanta patent invalid in Paxlovid suit against Pfizer](https://aibio.space/news/european-patent-court-rules-enanta-patent-invalid-paxlovid-suit/) The Unified Patent Court found the '265 Patent invalid on Pfizer's counterclaim and called Enanta's infringement action unfounded. ## Latest Enanta Pharmaceuticals news 1. 2026-07-02 Financings [Enanta Pharmaceuticals files for up to $75,000,000 at-the-market stock sales](https://aibio.space/news/enanta-pharmaceuticals-files-up-75-000-000-market-stock-sales/) The company signed an Open Market Sale Agreement with Jefferies LLC on July 2, 2026. Jefferies is entitled to a commission of up to 3.0% of gross sales. 2. 2025-09-30 Financings [Enanta launches $50,000,000 stock offering, later prices $65,000,000](https://aibio.space/news/enanta-launches-50-000-000-stock-offering-later-prices-65-000-000/) The preliminary filing left price and share count blank. The final prospectus supplement, dated September 30, 2025, priced 6,500,000 shares at $10.00, with $61,100,000 going to the company before expenses. 3. 2025-08-20 Legal [Enanta files patent infringement suit against Pfizer over Paxlovid in EU Unified Patent Court](https://aibio.space/news/enanta-files-patent-infringement-suit-against-pfizer-paxlovid-eu/) Enanta Pharmaceuticals says it sued Pfizer Inc. and certain of its subsidiaries in the Unified Patent Court on Aug 20, 2025, alleging infringement of a European patent through Paxlovid sales. The claim is untested, and no hearing date is given. ## Enanta Pharmaceuticals at a glance - **Ticker**: ENTA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $189.5 million ### Related companies - [Spyre Therapeutics](https://aibio.space/companies/spyre-therapeutics/) NASDAQ: SYRE - [Artelo Biosciences](https://aibio.space/companies/artelo-biosciences/) NASDAQ: ARTL - [Amneal Pharmaceuticals](https://aibio.space/companies/amneal-pharmaceuticals/) NASDAQ: AMRX - [ACADIA Pharmaceuticals](https://aibio.space/companies/acadia-pharmaceuticals/) NASDAQ: ACAD - [CytomX Therapeutics](https://aibio.space/companies/cytomx-therapeutics/) NASDAQ: CTMX - [Oric Pharmaceuticals](https://aibio.space/companies/oric-pharmaceuticals/) NASDAQ: ORIC - [Relmada Therapeutics](https://aibio.space/companies/relmada-therapeutics/) NASDAQ: RLMD - [Atara Biotherapeutics](https://aibio.space/companies/atara-biotherapeutics/) NASDAQ: ATRA ### Also on NASDAQ - [Allarity Therapeutics](https://aibio.space/companies/allarity-therapeutics/) ALLR - [Geron](https://aibio.space/companies/geron/) GERN - [Oculis Holding](https://aibio.space/companies/oculis/) OCS - [Rocket One](https://aibio.space/companies/rocket-one/) RKTO - [BioNexus Gene Lab](https://aibio.space/companies/bionexus-gene-lab/) BGLC - [Schrodinger](https://aibio.space/companies/schrodinger/) SDGR ## Enanta Pharmaceuticals annual financials | Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 | |---|---|---| | Research and development | [$106.7 million](https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/) | [$131.5 million](https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/) | | Net income (loss) | [-$81.9 million](https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/) | [-$116.0 million](https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/) | | Cash from operations | [-$19.3 million](https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/) | [-$78.8 million](https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/) | | Cash and equivalents | [$32.3 million](https://www.sec.gov/Archives/edgar/data/1177648/000119312526345719/) | [$37.2 million](https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/) | | Short-term investments | [$156.6 million](https://www.sec.gov/Archives/edgar/data/1177648/000119312526345719/) | [$211.0 million](https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $33.4 million, plus short-term investments of $156.1 million, $189.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Enanta Pharmaceuticals Has Enanta Pharmaceuticals raised money recently? Our latest story on this, dated Jul 2, 2026: "Enanta Pharmaceuticals files for up to $75,000,000 at-the-market stock sales". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/enanta-pharmaceuticals-files-up-75-000-000-market-stock-sales/). Is Enanta Pharmaceuticals involved in a lawsuit? Our latest story on this, dated Aug 20, 2025: "Enanta files patent infringement suit against Pfizer over Paxlovid in EU Unified Patent Court". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/enanta-files-patent-infringement-suit-against-pfizer-paxlovid-eu/). What is the ticker symbol of Enanta Pharmaceuticals? Enanta Pharmaceuticals, Inc. trades under the ticker ENTA on NASDAQ. Where is Enanta Pharmaceuticals listed? Enanta Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:9EP. What is the SEC CIK of Enanta Pharmaceuticals? The SEC Central Index Key (CIK) for Enanta Pharmaceuticals, Inc. is 1177648. Its filings are on SEC EDGAR. How many shares does Enanta Pharmaceuticals have outstanding? 29,125,402 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Enanta Pharmaceuticals listed under? Our directory records Enanta Pharmaceuticals, Inc. under United States. What does Enanta Pharmaceuticals do? Our directory classifies Enanta Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Enanta Pharmaceuticals? The ISIN recorded for Enanta Pharmaceuticals, Inc. is US29251M1062. Does aibio.space cover Enanta Pharmaceuticals? aibio.space lists Enanta Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Is Enanta Pharmaceuticals profitable? Enanta Pharmaceuticals, Inc. reported a net loss of $81.9 million for the fiscal year ended Sep 30, 2025, and used $19.3 million of cash in operations, per its annual report to the SEC. How much does Enanta Pharmaceuticals spend on research and development? $106.7 million in the fiscal year ended Sep 30, 2025, per its annual report. How much cash does Enanta Pharmaceuticals have? $189.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Enanta Pharmaceuticals (ENTA) stock news? Our latest story on Enanta Pharmaceuticals, dated Oct 29, 2026: "European patent court rules Enanta patent invalid in Paxlovid suit against Pfizer". The Unified Patent Court found the '265 Patent invalid on Pfizer's counterclaim and called Enanta's infringement action unfounded. [Source](https://aibio.space/news/european-patent-court-rules-enanta-patent-invalid-paxlovid-suit/). Is Enanta Pharmaceuticals a smaller reporting company? SEC records list Enanta Pharmaceuticals, Inc.'s filer category as: Non-accelerated filer
Smaller reporting company. ## Investor discussion: Enanta Pharmaceuticals Members talk about Enanta Pharmaceuticals (ENTA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Enanta Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-10-29 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1177648/000119312526437774/enta-20261029.htm) 2. 2026-07-02 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1177648/000119312526294828/d17914d424b5.htm) 3. 2025-09-30 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1177648/000119312525225149/d16379d424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ENTA on TradingView](https://www.tradingview.com/symbols/NASDAQ-ENTA/). ## SEC filings and registration - **SEC name**: Enanta Pharmaceuticals Inc - **CIK**: 1177648 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ENTA (Nasdaq) - **Fiscal year ends**: September 30 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 4 KINGSBURY AVENUE, WATERTOWN, MA, 02472 - **Phone**: 617 607 0800 - **Shares outstanding**: 29,125,402 as of 2026-08-07 (10-Q filed 2026-08-12) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1177648/000119312526345719/enta-20260630.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-20260810.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1177648/000119312526294837/d123412d8k.htm) filed 2026-07-02 - [424B5](https://www.sec.gov/Archives/edgar/data/1177648/000119312526294828/d17914d424b5.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1177648/000119312526279803/d133783d8k.htm) filed 2026-06-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1177648/000119312526274950/d159604d8k.htm) filed 2026-06-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1177648/000119312526220572/enta-20260331.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1177648/000119312526216735/enta-20260511.htm) filed 2026-05-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001177648), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Enanta Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ENTA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Enanta Pharmaceuticals, Inc. - **Ticker**: ENTA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US29251M1062 - **Other listed symbols**: GETTEX:9EP - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ENTA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/enanta-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Enanta Pharmaceuticals (ENTA) news: offering and lawsuit", 2026-10-31, https://aibio.space/companies/enanta-pharmaceuticals/